Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss from operations | NaN | -1,471,268 | -12,081,066 | NaN |
| Sale of royalty and milestone rights, net | NaN | 0 | 0 | NaN |
| Interest expense | NaN | 206,955 | 615,754 | NaN |
| Interest income | NaN | 233,936 | 445,804 | NaN |
| Other income (expense), net | NaN | 589,489 | -293,460 | NaN |
| Loss on disposal of property and equipment | NaN | 0 | 0 | 0 |
| Net loss | -2,999,889 | -1,441,718 | -3,562,766 | -8,394,790 |
| Depreciation and amortization | 554,643 | 534,395 | 481,906 | 618,185 |
| Deferred financing cost amortization | NaN | NaN | 124,251 | 11,622 |
| Right-of-use assets - operating lease | -128,324 | -134,646 | -130,958 | -251,291 |
| Stock-based compensation expense | 455,064 | 357,160 | 403,027 | 736,375 |
| Non-cash royalty revenue related to sale of future royalties | 2,708 | -10,755 | 202 | 4,255 |
| Non-cash interest expense | 14,809 | -105,191 | 62,306 | 125,387 |
| Accounts receivable | 120,633 | 12,053 | NaN | 0 |
| Other receivables | -5,938 | 191,851 | 181,041 | -41,866 |
| Prepaid expenses | 378,471 | -114,230 | -84,506 | -469,750 |
| Deposits | 0 | 0 | NaN | 0 |
| Other current assets | 194,717 | 12,246 | 53,159 | NaN |
| Other non-current assets | 1,436,824 | 35,071 | 72,722 | -29,070 |
| Operating lease liabilities | -145,108 | -143,406 | -138,894 | -266,338 |
| Accounts payable | -44,782 | -621,272 | 518,208 | -152,082 |
| Accrued expenses | -13,338 | -1,244,389 | -618,168 | -388,070 |
| Interest payable | 158,042 | 154,554 | 149,269 | 268,738 |
| Deferred grant funding | 1,500,994 | -5,094,190 | -2,230,386 | 4,234,748 |
| Deferred revenue | NaN | -1,000,000 | NaN | NaN |
| Net cash used in operating activities | -5,520,644 | 1,444,264 | -442,135 | -10,887,999 |
| Purchases of property and equipment | 0 | 206,641 | 174,702 | 3,935 |
| Net cash used in investing activities | 0 | -206,641 | -174,702 | -3,935 |
| Net proceeds from issuance of common stock | 94,887 | 20,930,126 | NaN | NaN |
| Net proceeds from issuance of series a convertible preferred stock and warrants in connection with regulation a financing | 297,213 | NaN | NaN | NaN |
| Net proceeds from issuance of common stock | NaN | NaN | 18,744,042 | 911,261 |
| Payments of deferred offering costs | 28,500 | 321,686 | NaN | NaN |
| Repayment of liability on sale of future royalties | 0 | 0 | 0 | 0 |
| Issuance of note payable | NaN | 1 | 486,720 | NaN |
| Payments on note payable | 182,521 | 182,521 | 121,680 | 249,628 |
| Principal payments on financing lease | 896,549 | 346,488 | 458,850 | 458,850 |
| Net cash (used in) provided by financing activities | -715,470 | 424,129 | 18,650,232 | 202,783 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 44,542 | -25,657 | 6,860 | 25,983 |
| Net change in cash, cash equivalents and restricted cash | -6,191,572 | 1,636,095 | 18,040,255 | -10,663,168 |
| Cash, cash equivalents and restricted cash, beginning of period | 25,011,356 | 23,375,261 | 15,998,174 | NaN |
| Cash, cash equivalents and restricted cash, end of period | 18,819,784 | 25,011,356 | 23,375,261 | NaN |